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Introduction
Perioperative hyperglycaemia is a complex and common 
clinical problem, with serious adverse consequences for 
patient morbidity and mortality. A clinical approach to 
diagnosis, screening and management is offered.
Perioperative hyperglycaemia is a very common 
problem, both because the incidence may be increasing 
worldwide,1 and because it describes a much wider 
problem than diabetes mellitus only.
Incidence
Figures for the incidence of diagnosed diabetes mellitus in 
the USA range between 10-13%,2,3 and in the UK between 
2-5%.3,4 The World Diabetes Foundation estimated that in 
2010 the global prevalence of diabetes was 6.4%, and that 
the prevalence of diagnosed diabetics in Africa was 3.8%. 
However, the World Diabetes Foundation claims that more 
than 85% of diabetics in South Africa are undiagnosed.5 
In 2008, Biccard found the incidence of diabetes among 
South African patients with peripheral artery disease to be 
approximately 36%.1
Classification and diagnosis
The American Diabetes Association (ADA) classifies 
diabetes into four clinical classes:6
1. Type 1 diabetes results from pancreas beta cell 
destruction, usually leading to an absolute insulin 
deficiency.
2. Type 2 diabetes results from a progressive insulin 
secretory defect on the background of insulin 
resistance.
3. Specific types of diabetes are due to other causes, 
including genetic defects in beta cell function, 
genetic defects in insulin action, diseases of the 
exocrine pancreas (such as cystic fibrosis), and 
drug- or chemical-induced (such as in the treatment 
of human immunodeficiency virus (HIV)/acquired 
immune deficiency syndrome (AIDS), or after organ 
transplantation).
4. Gestational diabetes mellitus (GDM). This refers to 
diabetes diagnosed in pregnancy that is not clearly 
overt diabetes.
Since 2009, the ADA criteria for the diagnosis of diabetes 
have included a glycosylated haemoglobin A1c (HbA1c) 
> 6.5%.6
The Society for Endocrinology, Metabolism and Diabetes 
of South Africa (SEMDSA) does not include the HbA1c, but 
their guidelines are currently being reviewed, and the 
updated guidelines will be published shortly.7
While HbA1c is a useful tool, currently it is not recommended 
to delay elective surgery until glycaemic correction of 
elevated HbA1c levels is achieved.
2,4 
American Diabetes Association criteria for the diagnosis 
of diabetes6
• The American Diabetes Association criteria for the 
diagnosis of diabetes is a HbA1c ≥ 6.5%. The test should 
be performed in a laboratory using a method that is 
National Glycohemoglobin Standardization Program 
certified, and standardised to the Diabetes Control 
and Complications Trial assay.*
OR
• A fasting plasma glucose (FPG) ≥ 126 mg/dl (7 mmol/l). 
Fasting is defined as no caloric intake for at least 
8 hours.*
OR
• A two-hour plasma glucose ≥ 200 mg/dl (11.1 mmol/l) 
during an oral glucose tolerance test (OGTT). The test 
should be performed as described by the World Health 
Organization (WHO), using a glucose load containing 
the equivalent of 75 g anhydrous glucose dissolved in 
water.*
OR
• In a patient with classic symptoms of hyperglycaemia 
or hyperglycaemic crisis, a random plasma glucose 
≥ 200 mg/dl (11.1 mmol/l).* 
*In the absence of unequivocal hyperglycaemia, the 
result should be confirmed by repeat testing.
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The Society for Endocrinology, Metabolism and Diabetes 
of South Africa criteria for the diagnosis of diabetes 
mellitus7
A. Symptoms of diabetes
The classic symptoms of diabetes, including polyuria, 
polydipsia and weight loss.
PLUS
• Casual or random plasma glucose ≥ 11.1 mmol/l. 
“Casual” is defined as any time of the day, regardless 
of the time of last meal. 
OR
• FPG ≥ 7.0 mmol/l. “Fasting” is defined as no caloric 
intake for at least 8 hours.
OR
• Two-hour plasma glucose  ≥ 11.1 mmol/l during OGTT 
The test should be performed as described by the 
WHO using a glucose load containing the equivalent 
of 75 g anhydrous glucose dissolved in 250 ml water 
over five minutes. Note: In the absence of unequivocal 
hyperglycaemia accompanied by acute metabolic 
decompensation, a confirmatory laboratory glucose 
test (a FPG, a casual plasma glucose, or a two-hour 
plasma glucose in a 75 g OGTT) must be carried out in 
all cases on a different day. Different criteria are used 
to diagnose gestational diabetes in pregnant women.
B. If asymptomatic
The 75 g OGTT is indicated in the following:
• In asymptomatic high-risk individuals.
• If the FPG is 5.6-7. mmol/l in detection or screening 
programmes.
• If random plasma glucose is 5.6-11.1 on screening. 
Alternatively, a FPG is indicated in this group.
The WHO 1998/2006 criteria should be used to diagnose 
diabetes. This emphasises the importance of not 
diagnosing diabetes on the basis of a single laboratory 
measurement in the absence of symptoms.
Diagnosis should be based on laboratory plasma glucose 
(preferred) or capillary plasma glucose.
Conversion factor: plasma glucose (mmol/l) = 0.102 + 
1.066 x capillary blood glucose.
In addition to the above group of patients with diabetes, 
a further two groups of patients with perioperative 
hyperglycaemia exist. The first is the group of patients 
who are not diabetic, but who have an increased risk of 
diabetes (pre-diabetic), and the second is the patient 
group with stress-induced hyperglycaemia.2,6
Patients with an increased risk of diabetes (prediabetes) 
are those with impaired fasting glucose (IFG) or impaired 
glucose tolerance (IGT) levels to the oral glucose tolerance 
test.2,6 While these patients’ glucose levels do not meet 
the criteria for diabetes, they are too high to be classified 
as normal. The ADA defines patients as having impaired 
fasting glucose (IFG) if they have a FPG between 100 mg/
dl-125 mg/dl (5.6 mmol/l - 6.9 mmol/l), and having IGT if 
they have a two-hour plasma glucose in the 75 g OGTT of 
140 mg/dl-199 mg/dl (7.8 mmol/l-11 mmol/l). The ADA also 
recognises patients with an HbA1c level between 5.7-6.4% 
as being pre-diabetic.6
Patients with stress-induced hyperglycaemia present 
with in-patient hyperglycaemia, which normalises when 
the admission-related stressor abates. Hyperglycaemia 
in these patients occurs in the face of a normal HbA1c, 
and  can have a worse outcome than hyperglycaemia 
in patients with diabetes.2,8 This suggests a different 
pathophysiology to that of diabetes mellitus.2,8 Nyika et 
al found that stress-induced hyperglycaemia occurred in 
healthy bungee jumpers, who did not have diabetes. This 
was due to decreased pancreatic beta cell function and 
insulin resistance, as a result of the stress experienced at 
the time of bungee jumping.9
Screening
Any patient with a random glucose ≥ 180 mg/dl 
(10 mmol/l)2 and/or patients who are identified by the 
ADA “criteria for testing for diabetes in asymptomatic 
adult individuals”2,6 should be screened for undiagnosed 
diabetes preoperatively. This includes the ADA criteria for 
testing for diabetes in asymptomatic adult individuals.6
ADA criteria for testing for diabetes in asymptomatic 
adult individuals6
1. Testing should be considered in all adults who are 
overweight [body mass index (BMI) ≥ 25 kg/m2] and 
who have one or more additional risk factors:
• Physical inactivity
• First-degree relative with diabetes
• High-risk ethnic group
• Women who delivered a baby > 4.08 kg, or who were 
diagnosed with GDM
• Hypertension [blood pressure (BP) > 140/90 mmHg, or 
on treatment for hypertension]
• High-density lipoprotein (HDL) cholesterol < 35 mg/dl 
(0.90 mmol/l), and/or a 
•  triglyceride level > 250 mg/dl (2.82 mmol/l)
• Women with polycystic ovary syndrome
• HbA1c ≥ 5.7%, IGT or IFG on previous testing
• Other clinical conditions associated with insulin 
resistance, e.g. severe obesity and acanthosis 
nigricans.
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• History of cardiovascular disease
2. In the absence of the above criteria, testing for 
diabetes should begin at age 45 years.
3.  If results are normal, testing should be repeated at 
three-year intervals, and consideration should be 
given to more frequent testing depending on initial 
results (e.g. those with prediabetes should be tested 
yearly) and risk status.
A corresponding set of criteria for children are also listed 
on the ADA website.
Clinical problems
Diabetes and hyperglycaemia present a complex set of 
clinical problems.
Uncontrolled diabetes reduces afflicted patients’ life 
expectancy by a mean of 15 years, and raises morbidity 
due to vascular and neuropathic complications by three 
to four times than that of a non-diabetic population.10
Complications of poorly controlled hyperglycaemia 
include the acute manifestations of dehydration and 
metabolic dysfunction of ketoacidosis (DKA), hyperosmolar 
non-ketotic coma and lactic acidosis. These patients also 
suffer chronic problems of wound infection, delayed 
wound healing, as well as chronic target organ damage, 
such as cardiovascular disease, cerebrovascular disease, 
renal disease, autonomic neuropathy and retinopathy.3
In South Africa, the mortality that is secondary to diabetes 
and diabetic complications is higher than international 
standards. The reasons for this include generally poor 
glycaemic control, poor monitoring of associated 
complications, and inadequate management of 
hypertension and hypercholesterolaemia.1,11
In chronic diabetics with recently diagnosed hypertension, 
even moderate control of the hypertension is more 
important for a better outcome than an emphasis on 
glycaemic control alone.3
In known diabetics, there should be a high index of 
suspicion for associated cardiovascular disease. Any 
patient with autonomic neuropathy or any other two 
myocardial ischaemia risk factors (smoking, raised chol-
esterol, dyslipidaemia, hypertension, a family history of 
coronary artery disease or males > 40 years of age) should 
be further evaluated by cardiovascular stress testing for 
ischaemic heart disease.3
Control of hyperglycaemia
In 2001, Van den Berghe advocated the control of 
hyperglycaemia with a “tight” glucose control regimen 
(80-110 mg/dl,  4.4-5.6 mmol/l). This has been modified 
to a “moderately tight” regime over the latter half of the 
previous decade.2,12  The current British National Health 
Service (NHS) guideline, the Management of adults with 
diabetes undergoing surgery and elective procedures, 
recommends keeping the glucose level between 
6-10 mmol/l, with the acceptable range being 
4-12 mmol/l.2,4
The problem with tight control was an incidence of 
dangerous hypoglycemia of 9-17%,4 with no improved 
outcome in terms of mortality and morbidity, except for 
a reduction in wound infection.12 Also, the original study 
was carried out in an intensive care (ICU) setting, and then 
extrapolated to non-ICU patients, resulting in a weak level 
of evidence for theatre use.
Subsequent studies have revealed that the deleterious 
effects of hyperglycaemia seem to occur from a glucose 
level of 9 mmol/l or greater.4
Furthermore, the Society for Ambulatory Anesthesia 
(SAMBA) consensus statement on perioperative 
blood glucose management in patients with diabetes 
undergoing ambulatory surgery recommends that 
patients with poorly controlled diabetes, who have to 
undergo surgery, are maintained at the higher end 
of the target blood glucose range, nearer their usual 
baseline value. This is because these patients have an 
altered counter-regulatory response which may result in 
hypoglycaemic symptoms developing at normal blood 
glucose levels.13 These patients’ intraoperative glucose 
requirements may also be higher than their postoperative 
requirements, further strengthening the argument for a 
“high-normal” intraoperative blood glucose target. A 
stable glucose level, albeit at the “high-normal” end of 
the range, ensures a far superior outcome than marked 
blood glucose fluctuations which may occur in the setting 
of a more tight control regimen.14
A relatively recent advance, incretin therapy, is used in 
type 2 diabetics to elicit the “incretin effect”.
Glucagon-like peptide 1 (GLP-1) is a naturally occurring 
incretin hormone secreted by the small intestine in 
response to an oral glucose stimulus. GLP-1 levels rise 
well before the blood glucose level rises. GLP-1 stimulates 
insulin secretion by the beta cells of the pancreas, inhibits 
glucagon secretion by the alpha cells of the pancreas, 
delays gastric emptying (so reducing postprandial 
hyperglycaemia), and reduces appetite and food 
intake.10,15,16
GLP-1 is inactivated in the body by the enzyme dipeptidyl-
peptidase-4 (DPP-4).
Exogenous incretin therapy is achieved by either the 
injection of GLP-1 analogues or the oral administration of 
DPP-4 inhibitors.10,15,16
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A full discussion of the detailed perioperative management 
of diabetic medication and fluid prescription, glucose 
and electrolyte monitoring and control, starvation and 
theatre list booking guidelines, is beyond the scope of this 
article, but a full set of detailed protocols may be found 
in the NHS April 2011 Management of adults with diabetes 
undergoing surgery and elective procedures: improving 
standards guidelines.4
Important aspects covered therein include:4
• Consideration should always be given to DKA, and 
surgery postponed, until this is under control.
• Glucose should be monitored hourly on the day 
of surgery unless hypoglycaemia occurs, in which 
case more frequent monitoring is required until 
normoglycaemia is achieved.
• Vigilance should be exercised to avoid hypoglycaemia.
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